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EnvironmentalEndocrine screening assays not only provide mechanistic information on the potential of a substance to
interact with the endocrine system, but also data potentially relevant for risk assessment. However, these
screening assays have a number of limitations that should be considered before the direct use of such
data for risk assessment purposes. This paper discusses the limitations that should be considered for both
human and environmental risk assessment. A proposal is made to provide an objective and transparent
process in order to consider which endpoint(s) might be incorporated into a risk assessment, and when
more deﬁnitive studies may be of value. The proposal is complemented with an easy-to-follow ﬂowchart
to aid industry scientists and regulators when evaluating the relevance of these data. Such an approach is
necessary to ensure the appropriate use of screening data to further our understanding of the eco/
toxicological proﬁle of substances undergoing screening.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The Organization for Economic Co-operation and Development
(OECD) and United States Environmental Protection Agency
(US-EPA) have both developed a suite of screening assays for use
in endocrine screening programmes of chemicals. Examples of
such programmes are US-EPA’s Endocrine Disruptor Screening
Programme1 and Japan’s ExTEND programme.2 These assays may
also be required under different European regulations (COM, 1999)
following concerns raised by the evaluation of a substance. The pri-
mary purpose of these screening assays is to establish if a substance
has the potential to interact with the endocrine system. Currently
this covers interactions with oestrogen and androgen pathways
and the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-
pituitary-thyroid (HPT) axes. An evaluation of the screening assays
outcomes alongside other relevant information is then used to
trigger appropriate higher tier or deﬁnitive tests to conﬁrm whether
the identiﬁed endocrine activity leads to an adverse effect in an
intact organism (Bars et al., 2011, 2012). These higher tier tests are
used for regulatory action according to region and substance speciﬁc
legislation. This may be a scientiﬁc risk assessment (e.g. in the USand Japan) or a hazard based restriction, without risk assessment,
in the European Union (Wheeler et al., 2012).
Despite the original purpose of the in vivo mammalian, ﬁsh and
amphibian screening assays in current regulatory programmes as
described above, there has also been interest in using certain data
from these assays for risk assessment (Dang et al., 2011; US-EPA,
2013a). In principle, the use of relevant data from screening assays
is an interesting proposition, making use of all the available
information on a speciﬁc substance for human and environmental
risk assessment. This is particularly important in the ecotoxicology
area, where the endocrine screens provide information on
endpoints (e.g. ﬁsh reproduction) and a taxon (amphibia) not
routinely required for the evaluation of substances. Nevertheless,
the limitations of the assays concomitant with their primary
purpose, screening for endocrine activity, should be carefully
considered when interpreting whether the data are relevant for
risk assessment. This paper highlights some key limitations of
using these screening assays for risk assessment purposes for both
the toxicological and ecotoxicological areas. It also makes a
proposal on how these data can be effectively integrated into an
assessment.2. Toxicology
The Hershberger (OCSPP, 2009c; OECD, 2009a), uterotrophic
(OECD, 2007; OCSPP, 2009f) and male and female pubertal assays
Table 1
Summary of the mammalian endocrine screening assays.
Mammalian screens
Study type Hershberger assay Uterotrophic assay Male pubertal assay Female pubertal assay
Relevant
regulatory
guidelines
OECD 441, OCSPP 890.1400 OECD 440, OCSPP
890.1600
OCSPP 890.1500 OCSPP 890.1450
No. treatments 2 for androgenicity
3 for anti-androgenicity
2 2 2
Recommended
spacing
factor
3 (0.5 log) 3 (0.5 log) 2 2
Animals/
replicate
6
orchidoepididymectomised
male rats
6 ovariectomised/
immature female rats
15 prepubertal male rats 15 prepubertal female rats
Mandatory
endpoints
Mortality, clinical signs,
body weight, food
consumption, weights of 5
androgen-dependent organs
Mortality, clinical
signs, body weight,
food consumption, wet
and blotted uterus
weights
Mortality, clinical signs, body weight, food
consumption, age and body weight at
preputial separation, seminal
vesicle + coagulating glands weight, ventral
and dorsolateral prostate weights, levitator
ani/bulbocavernosus muscle complex
weight, epididymides weights and
histology, testes weights and histology,
thyroid weight and histology, liver weight,
kidney (paired) weight and histology,
pituitary weight, adrenal (paired) weight),
serum testosterone, T4 and TSH, clinical
chemistry panel including creatinine and
blood urea nitrogen
Mortality, clinical signs, body weight, food
consumption, age and body weight at
vaginal opening, uterus weight and
histology, ovary (paired) weight and
histology, thyroid weight and histology,
liver weight, kidney (paired) weight and
histology, serum T4 and TSH, assessment of
oestrus cyclicity, clinical chemistry panel
including creatinine and blood urea
nitrogen
Optional
endpoints
Liver weight, kidney (paired)
weight, adrenal (paired)
weight, serum testosterone,
serum luteinizing hormone
Histopathological
evaluation of uterus
and vagina
None speciﬁed None speciﬁed
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that use mammalian species explicitly for endocrine screening.
These assays are described brieﬂy in Table 1.2.1. Intact status of the test animals
The Hershberger and uterotrophic assays commonly use
gonadectomised rodents in order to produce exquisitely sensitive
model organisms for evaluation of (anti)androgenicity and oestr-
ogenicity, respectively. These animal models cannot be consid-
ered physiologically-relevant owing to the lack of a functional
hypothalamic-pituitary-gonadal (HPG) axis. The lack of physiolog-
ical relevance of these models is recognised in the most widely
accepted deﬁnition of an endocrine disruptor, which states that
an adverse effect must be observed in an intact organism in order
to be considered truly relevant (IPCS, 2002). Hence, results of the
Hershberger and uterotrophic assays using surgically modiﬁed
animals can only be used to help investigate potential mecha-
nisms as part of a broader investigation and should not be used
in risk assessment.2.2. Single time point assessments of hormones
The male and female pubertal assays both require that thyroid
stimulating hormone (TSH) and thyroxine (T4) be measured at ter-
mination. In addition, testosterone measurements are also
required in the male pubertal assay. Although the relevant guide-
lines make some effort to control for the high level of intrinsic var-
iability of these hormones, a single time point assessment is
insufﬁcient to reliably assess effects on these parameters, making
them unsuitable for use in risk assessment, as highlighted in Box 1.Box 1. Pubertal assays summarising the issues around hor-
mone measurements
Test Guideline Requirements
The male and female pubertal assays both require that
thyroid stimulating hormone (TSH) and thyroxine (T4) be
measured at termination. In addition, testosterone measure-
ments are also required in the male pubertal assay.
Significant Issues
Hormone levels demonstrate a high level of variability,
both between individuals but also the same individual at dif-
ferent times of the day, as well as being sensitive to other fac-
tors, such as when the animal last ate. Such factors mean that
when measured in toxicology studies, these endpoints can
show extremely high variability. Examples of the extreme
variability in these endpoints are exemplified in the guideline
for the male pubertal assay, which specifies control ranges
for Sprague Dawley rats of 4.212–24.112 ng/mL and 0.260–
3.960 ng/mL for TSH and testosterone, respectively, with
coefficients of variation of 34.04% and 58.82%, respectively.
Conclusions
Owing to their extreme variability, apparent effects on
hormone levels should not be used as endpoints for risk
assessment, particularly in the absence of any correlating
functional effect. Although the reliability of hormonal mea-
surements would be increased greatly by sampling multiple
times over the course of the study, the relatively high vol-
umes of blood required for hormonal analyses and the addi-
tional stress involved in taking these samples preclude this
approach from being taken in these studies, which use poten-
tially sensitive juvenile animals, as well as assessing a num-
ber of parameters which are known to be significantly
affected by stress, including the hormone levels themselves.
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Some regulatory paradigms, such as the US-EPA’s Food Quality
Protection Act (FQPA), require an additional safety factor for chem-
icals for which effects in juveniles are noted at lower dose levels
than in parents. This additional safety factor, usually 10, is applied
to endpoints used in risk assessments. The male and female
pubertal assays are the ﬁrst regulatory assays in which effects are
assessed in juveniles only, with no concurrent testing of adult ani-
mals. This severely limits their potential to identify novel or lower
dose effects in juvenile animals, with comparison to existing data
being very difﬁcult as these studies use atypical durations of expo-
sure (21 and 31 days of exposure for females and males, respec-
tively) and often different routes of exposure, which can result in
very different toxicokinetics, when compared to existing data. For
example, short-term studies of plant protection product active sub-
stances typically use a dietary route of exposure whereas the male
and female pubertal assays use oral gavage dosing. The former is
consistent with European guidance in the environmental area
where endpoints from dietary exposed mammal and bird studies
are given preference over gavage derived endpoints (EFSA, 2010).
3. Ecotoxicology
The ﬁsh short term reproduction assay (FSTRA) and amphibian
metamorphosis assay (AMA) are the ﬁrst assays with regulatory
guidelines that use non-mammalian vertebrate species to screen
for endocrine activity. These assays, described brieﬂy in Table 2,
measure a range of both apical and mechanistic endpoints. In the
context of this paper apical is taken to mean measures related to
population level adverse effects on survival, growth, development
and reproduction. It is generally accepted that the mechanistic his-
topathological and biochemical endpoints from either screening or
deﬁnitive level tests are not adverse effects per se and so should not
be used directly in risk assessment (Hutchinson et al., 2006).Table 2
Summary of the ecotoxicological endocrine screenings assays. Codes represent the differe
Study type Ecotoxicology screens
Fish screens
Relevant regulatory
guidelines
OECD TG 230 OECD TG 229
No. treatments 3 and control(s) 3 and control(s)
Recommended spacing
factor
3.2–10 3.2–10
Replication 2 (ZF)
4 (FHM; MD)
2 (ZF)
4 (MD and FHM)
Animals/replicate 10 (ZF; MD)
6 (FHM)
10 (ZF)
6 (MD; FHM)
Males/replicate 5 (ZF)
3 (MD)
2 (FHM)
5 (ZF)
3 (MD)
2 (FHM)
Females/replicate 5 (ZF; MD)
3 (MD)
4 (FHM)
5 (ZF)
3 (MD)
4 (FHM)
Apical endpoints Mortality
Behaviour
Mortality
Behaviour
Fecundity
Mandatory diagnostic
endpoints
Secondary sexual characteristics
(FHM; MD)
Vitellogenin
Secondary sexual c
(FHM; MD)
Vitellogenin
Optional diagnostic
endpoints
Gonadal histopathology* Gonadal histopatho
* Certain histopathological ﬁndings may be considered diagnostic of endocrine activity3.1. Limited proportion of the life-cycle
Both the ﬁsh and amphibian screening assays are 21 days in
duration. In the case of the ﬁsh screening assay sexually mature
ﬁsh are used, excluding known sensitive early life-stages
(McKim, 1977). This adult life-stage is not optimised for detecting
impacts on growth as the organisms are adult and not in an expo-
nential growth phase. The life-stage tested in the screening
assay(s) is therefore not necessarily the most sensitive, depending
on the mode of action of the test substance. In a complimentary
sense (i.e. supporting evidence of new data on the same endpoint),
the relevant endpoints are already available from chronic testing
conducted previously for the standard registration package.
Therefore, we believe where higher tier tests designed speciﬁcally
to measure apical endpoints are available, they should take
precedence in deriving the endpoints for use in risk assessment.
The points outlined below further support this conclusion.
3.2. General low replication and low numbers of animals used
Another factor of the assaysbeingdesignedas screeningmethods
is the low level of replication employed; see Tables1 and2 for a sum-
mary across themammalian and ecotoxicology assays, respectively.
Many of the assays use only two replicates per treatment level,
yielding limited power to detect changes in often variable parame-
ters. Further, the assays, rightly in terms of animal welfare, use lim-
ited numbers of test organisms. This is of little consequence in terms
of detecting effects on the mechanistic endpoints. For instance
detection of vitellogenin induction inmale ﬁsh following oestrogen-
ic exposure requires very lowpower (e.g. 2malesper replicate is suf-
ﬁcient) as the magnitude of the response can be from barely
detectable (0.02–0.04 ng/ml) to milligrams per millilitre blood
plasma (e.g. 1 million fold change) (Wheeler et al., 2005). However,
detecting relatively small but signiﬁcant changes in growth using so
few animals is unreliable and any statistically signiﬁcant effectnt ﬁsh species: Fathead minnow (FHM), medaka (MD) and zebraﬁsh (ZF).
Amphibian screens
OCSPP 890.1350 OECD TG 231 and OCSPP
890.1100
3 and control(s) 3 and control(s)
10 3.3–10
4 (FHM) 4
6 (FHM) 20
(5 at day 7
15 at day 21)
2 (FHM) –
4 (FHM) –
Mortality
Behaviour
Fecundity
Fertilisation success
Body weight
Body length
Gonadal somatic index
Mortality
At 7 and 21-days:
Developmental stage
Hind limb length
Snout-vent length
Body weight
haracteristics Secondary sexual
characteristics (FHM)
Vitellogenin
Gonadal histopathology*
Thyroid gland
histopathology
logy* Plasma sex steroids –
see (OECD, 2010).
292 J.R. Wheeler et al. / Regulatory Toxicology ashould be treated with caution. A good example highlighting this
issue is the measurement of growth in the US version of the Fish
Short-Term Reproduction Assay (FSTRA) (OCSPP, 2009b) (note that
growth is not included as an endpoint in the OECD versions of the
assay (OECD, 2009b, 2012b)) as described in Box 2.Box 2. Fish Short Term Reproduction Assay (FSTRA) (OCSPP,
2009b) summarising the issues around fish growth
Test Guideline requirements
The FSTRA requires that growth (body weight and length)
are measured as endpoints. Before the pre-exposure period
is initiated a sub-sample of the batch of fish is weighed to
ascertain whether males and females separately are within
approximately ±20% of the arithmetic mean weight. At the
test termination (after 21-days exposure) individual fish are
measured and weighed to the nearest 0.1 mm and 0.01 g
respectively. Statistical comparisons (each sex separately)
are made to the untreated control group(s).
Significant issues
 Numbers of individuals per replicate are low therefore
individual variability could be mistaken for a treatment
related effect
o For males there are only two individuals per replicate
(only 8 individuals per treatment) and for females
four individuals per replicate (only 16 individuals
per treatment).
j Males and females cannot be combined as there
is size sexual dimorphism in the test species.
o Compared to definitive tests optimised to measure
growth e.g. the fish early lifestage test (at least 60
individuals across at least 2 replicates) numbers of
individuals are insufficient (OCSPP, 1996; OECD,
2013).
 The fish are sexually mature (4.5–6 months old) so not in
an exponential growth phase
o Changes in length are unlikely.
o Changes in weight are most likely to represent
weight loss rather than a specific growth effect.
j These could be related to overt toxicity due to the
maximum test concentration setting guidance
rather than specific toxicity (Wheeler et al., 2013)
o Female weight data are likely to be highly variable
related to where sampling occurs relative to egg
release. This high measurement variability is also
captured in Gonadal Somatic Index data as a function
of spawn interval with the largest values occurring at
day 2 post-spawn, just prior to the interval of maxi-
mum spawning activity (Jensen et al., 2001).
Conclusions
Changes in length are unlikely. Changes in weight are
likely to be unreliable due to the low number of individ-
uals (particularly males). Female weight data are likely to
be highly variable due to the asynchronous 3–4 days
spawning cycle amongst females within and between rep-
licates or treatments relative to the test termination and
weight determination. Weight changes may occur due to
weight loss, most likely due to overt toxicity as systemi-
cally high test concentrations are likely due to the test
guideline concentration setting guidance (reviewed by
Wheeler et al., 2013). Consequently, it is unlikely that
growth data from an FSTRA will be suitable for risk
assessment.The Amphibian Metamorphosis Assay (AMA) (OCSPP, 2009a;
OECD, 2009c) uses a higher number of animals per replicate
(Table 2). However, due to the subsampling of individuals (5 per
replicate) after 7 days of exposure the numbers available for
growth and development determination are also limited (5 and
15 at days 7 and 21, respectively). These low numbers are further
exacerbated, at least for length measurements, by the common
phenomenon of spinal curvature or tail ﬂex. For instance, 15 out
of 18 studies reviewed by the US-EPA for the evaluation of the
AMA for its Endocrine Disruptor Screening Program indicated inci-
dences at varying levels of spinal curvature (US-EPA, 2013b). Prev-
alence of spinal curvature is most likely the result of dietary
deﬁciencies (Marshall et al., 1980; Leibovitz et al., 1982;
Martinez et al., 1992) but could potentially also have a genetic
component. Undoubtedly, further work to reduce the occurrence
by optimising feeding in the AMA will assist, but it is likely that
length measurements will be confounded using this test design
(raised as an issue at the Scientiﬁc Advisory Panel in the US3).
3.3. Limited number of treatment levels spaced by a large factor
The screening assays also employ large spacing factors between
the limited number of treatment levels in order to cover a broad
range of concentrations from the Maximum Tolerated Dose or Con-
centration (Hutchinson et al., 2009; Wheeler et al., 2013) down-
wards. Due to the limited number of test item treatment levels, a
dose or concentration response for apical endpoints is not always
observed. The spacing factors in the ecotoxicology endocrine
screens are typically a factor of 10 unless a particularly steep con-
centration-response relationship is expected (from pre-existing or
range-ﬁnding data) where it is lowered to 3. This contrasts to spac-
ing factors of between 2 and 2.2 for deﬁnitive ecotoxicological tests
used to derive endpoints for risk assessment. Larger factors for the
endocrine screens are appropriate and resource effective for the
purpose of hazard identiﬁcation i.e. determining if a substance
has a particular property (e.g. endocrine activity). However, for risk
assessment greater resolution is desirable. The screening assays
often do not capture the dose or concentration response relation-
ship for the apical endpoints and the large interval between treat-
ments means a NOEC is determined at 10-fold below the LOEC
when in reality it may be at a signiﬁcantly higher level. Such inac-
curate NOECs may lead to an overly conservative risk assessment.
4. Proposal for risk assessment inclusion
Considering the limitations of the screening assay designs to
measure risk assessment relevant effects, caution should be exer-
cised when screening assays generate the lowest endpoint for a
particular assessment i.e. when these drive the risk assessment.
Therefore, a thorough evaluation is required in order to come to
an objective and transparent decision.
We propose the following steps (as summarised in Fig. 1) which
may be of use to industry scientists and regulators when evaluat-
ing the relevance of these new data:
 Data reliability and quality check
The ﬁrst step should be to assure the reliability and quality of
the available screening studies. For regulatory studies that have
been conducted to internationally recognised guidelines (e.g.
OECD), and most probably to the principles of Good Laboratory
Practice, there should be a guideline compliance check. The
impact of any guideline deviations should be considered and
pragmatically evaluated for potential impact on the endpoints
of concern (see Chapter 4; OECD, 2012a). For literature studies
a transparent reliability and quality assessment should be
nd Pharmacology 69 (2014) 289–295
Fig. 1. Flowchart summarising a proposal to consider endpoints from endocrine
screening assays for use in risk assessment.
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scheme (Klimisch et al., 1997). Only studies that are guideline
compliant or considered of sufﬁcient quality (i.e. Klimisch cate-
gories 1 or 2) should be consider further (Mensink et al., 2008).
 Endpoint selection
Once a study is considered reliable it is then necessary to sort
which of the endpoints are potentially relevant for the human
or environmental risk assessment. There are signiﬁcant
differences between the human and environmental assess-
ments that are derived from the respective protection goals,
i.e. the individual or the population. Therefore, for the human
health assessment, in principle any endpoint is relevant.
Whereas, in the environmental area the focus is on endpoints
that are likely to impact at the population level (Weltje et al.,
2013a) such as survival, growth, development and reproduc-tion. Consequently, mechanistic endpoints such as vitellogenin,
gonadal histopathology and hormone measurements will not be
considered relevant for the environmental risk assessment
(Hutchinson et al., 2006).
 Endpoint evaluation
Both the statistical and biological qualities of the data (i.e. part
of a dose or concentration-response relationship, magnitude of
the response relevant, statistical power etc.) should be consid-
ered. Speciﬁcally considering the points of low replication,
low numbers of animals and/or high degree of biological varia-
tion discussed above. The biological signiﬁcance assessment
should carefully consider the (population) relevance of low
magnitude effects (small changes from control), against varia-
tion of historical control performance for that parameter. Also,
lower relevance to screening study endpoints is assigned where
existing studies optimised for a particular endpoint are avail-
able. A good example of this would be ﬁsh growth from a ﬁsh
short term reproduction study where an early life-stage test is
available (see Box. 2). Another example where biological
relevance should be carefully considered is where changes in
hormone levels are noted in the absence of any potentially-
related functional effect. Hormone measurements should be
interpreted with care bearing in mind the lack of population
relevance (adversity) in the environmental area, the high natu-
ral variation and need for an integrated measure over time for
human health. For all endpoints a consideration of the histori-
cal control database may be helpful in establishing both the
statistical and biological relevance of a given effect.
 Existing data and screen data endpoint comparison
Where the endpoint from the screening study is considered of
potential relevance for the risk assessment, LOEC/LOELs and
NOEC/NOELs across screening and deﬁnitive studies should be
considered collectively to determine the highest NOEC/NOEL
below the lowest LOEC/LOEL regardless of whether they were
determined in the same study. This approach is widely used
and accepted in toxicology (JMPR, 2004) and ecotoxicology
(EFSA, 2010) and often results in a higher NOEC/NOEL than
the lowest NOEC/NOEL by considering studies independently.
An example of a ﬁsh dataset is shown in Fig. 2. Where data from
an amphibian metamorphosis assay are concerned, endpoints
should be aligned with the ﬁsh dataset and any available
amphibian data, since there is strong evidence for comparable
ﬁsh and amphibian aquatic life-stage acute and chronic sensi-
tivity (Kerby et al., 2010; Weltje et al., 2013b).
 Risk assessment
If the outcome of the assessment across studies is that the
NOEC/NOEL of the screening study is indeed the lowest value,
it may be considered in the preliminary risk assessment. How-
ever, the large spacing factor may still be further reﬁned. A com-
monly used technique in the ecotoxicological area is to
calculate the geometric mean of the NOEC and LOEC concentra-
tions, which is equivalent to the Maximum Acceptable Toxicant
Concentration (MATC) or the Threshold Effect Concentration
(TEC) often used as a summary statistic for aquatic toxicity data
(Stephan et al., 1985). This calculation will correct for the large
spacing factor between concentrations that is typically
employed in the screening assays. It employs the geometric
mean rather than the arithmetic mean since it will always be
smaller than or at a maximum equal to the arithmetic mean
(Streiner, 2000). The resulting value may be used as a surrogate
NOEC in the risk assessment.
 Hazard and/or exposure reﬁnement (where necessary)
If the preliminary risk assessment indicates unacceptable risk or
uncertainty, it may be considered to conduct either a higher tier
study (e.g. a standard ﬁsh full life-cycle study) or a modiﬁed
screening assay focussed on the risk assessment relevant
Fig. 2. Graphical representation of a realistic overall NOEC determination from multiple studies. This fabricated dataset (standard ﬁsh full life-cycle test and short term
reproduction assay) demonstrates the principle of deriving the highest NOEC below the lowest LOEC. In this case the dotted line represents the realistic NOEC even though the
fecundity NOEC from the Fish Short Term Reproduction Assay yields the lowest NOEC (due to the large spacing factor employed).
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These approaches would determine a more accurate and precise
NOEC/NOEL. Alternatively, exposure reﬁnement could be under
taken to (further) improve the realism of exposure values or to
implement mitigation measures. Neither approach guarantees
that an acceptable risk will be demonstrated so expert
judgement as to the likelihood of success should be applied
before conducting additional vertebrate tests.
5. Discussion
Increasingly endocrine screening assay data will be available for
substances that undergo testing via screening programs or
substance speciﬁc requests. If these assays indicate that a sub-
stance has endocrine activity it is likely that higher tier tests will
be required to evaluate if the activity results in adverse effects in
comprehensive longer-term studies. In the human health area, at
least for data rich substances, these data may already be available
(Bars et al., 2011, 2012). These deﬁnitive studies will not only
inform on endocrine disruption but also provide endpoints suitable
for use in risk assessment. For substances that are deemed negative
in these endocrine screens, further testing will not necessarily be
performed. Therefore, there is interest in using apical effects data
from screening assays for risk assessment (Dang et al., 2011;
US-EPA, 2013a). However, since this was not the primary purpose
of the assays, there are a number of limitations that should be
considered before direct use of such endpoints in an assessment.
Several of the assays are not relevant at all as they are conducted
in over-sensitised, surgically modiﬁed organisms (i.e. the Hersh-
berger and uterotrophic assays). Some endpoints are known tobe highly variable and lack time course measurements also making
them unreliable for direct use in risk assessment (i.e. hormone
measurements in the pubertal assays). Further, there are issues
around assessing juvenile sensitivity and the impact this may have
on the risk assessment in some jurisdictions. In line with animal
welfare concerns, the screening assays attempt to limit the num-
bers of individuals and replication making the interpretation of
some effects challenging in terms of their statistical and biological
signiﬁcance. Unlike higher tier test designs, suitable for risk assess-
ment, the assays are limited to short proportions of the life-cycle
and are therefore not optimised for the measurement of some end-
points that may be considered in scope (e.g. growth). In the envi-
ronmental area the spacing factors between test item treatment
levels are also large (3.2–10) in the screening assay designs. There-
fore, any derived NOECs may be overly conservative compared to
those derived from deﬁnitive tests typically employing much smal-
ler spacing factors (2–2.2). Consequently, the proposal as outlined
in Fig. 1, aims to assess these factors in an objective and transpar-
ent manner. Hopefully such an approach will lead to good decision
making that ensures only appropriate data are carried forward to
risk assessment. Thereby, none of the new information generated
is ignored but rather integrated into our understanding of the
eco/toxicological proﬁle improving the overall risk assessment.6. Conclusions
Testing programmes such the US-EDSP mean large amounts of
new data are and will continue to be generated. We believe it is
important to carefully evaluate these data on two fronts: (1) Their
primary purpose (collectively with all existing information) as to
J.R. Wheeler et al. / Regulatory Toxicology and Pharmacology 69 (2014) 289–295 295whether the substance has the potential to interact with the endo-
crine system; and (2) whether any of the risk assessment relevant
data in these studies change our understanding of the (eco)toxico-
logical proﬁle and merit incorporation into the risk assessment. In
this on-going process it is important for regulatory and industry
scientists to ‘mind the gap’ to ensure the most appropriate use of
these data. This inevitably requires a transparent analysis of the
advantages and limitations of the assays and their individual end-
points. We hope this paper will help facilitate this debate as the
regulatory community begins to tackle these issues.References
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